[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544329":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":59,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c",null,"Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.",[13],"Drug: Glecaprevir-pibrentasvir",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Glecaprevir-pibrentasvir","Glecaprevir-pibrentasvir 100 mg \u002F 40 mg 3 tab orally (PO) once daily for 56 days.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Tracey Bach, MBA","CONTACT","314-273-6075","habrockt@wustl.edu",{"name":27,"role":23,"phone":10,"phoneExt":10,"email":28},"Laura Marks, MD, PhD","marks@wustl.edu",[30,49],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Barnes Jewish Hospital","RECRUITING","St Louis","Missouri","63110","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-90.19789,38.62727,{"lat":42,"lon":41},[45,47],{"name":46,"role":23,"phone":24,"phoneExt":10,"email":25},"Tracey Bach",{"name":27,"role":48,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":50,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Washington Univeristy",{"type":39,"coordinates":52},[41,42],{"lat":42,"lon":41},[55,57],{"name":56,"role":23,"phone":10,"phoneExt":10,"email":28},"Laura Marks, MD,PhD",{"name":58,"role":23,"phone":24,"phoneExt":10,"email":25},"Tracey Habrock-Bach, MBA",{"type":60,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100544329","feasibility-and-acceptability-of-hcv-treatment-in-pregnancy-100544329",false,"NCT06367465","Feasibility and Acceptability of HCV Treatment in Pregnancy","Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy Feasibility and Acceptability of Early Linkage to HCV Treatment in Pregnancy","Inclusion Criteria:\n\n* Female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use.\n\nExclusion Criteria:\n\n\\-","FEMALE","18 Years",{"count":71,"type":72},50,"ESTIMATED","OBSERVATIONAL","Pregnant adults over the age of 18 who are seen in the Washington University obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to BJH with hepatitis C virus infection who have a history of past or current drug use\n\nParticipant Duration: Approximately 1 year.\n\nAims:\n\nAim 1 - Evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs.\n\nAim 2 - Evaluate patient experience with hepatitis C virus treatment during pregnancy.",[76,77],"Hepatitis C","Pregnancy Complications","2026-06-05",{"date":80,"type":81},"2026-06-09","ACTUAL",{"date":83,"type":81},"2024-02-01",{"date":85,"type":72},"2026-12-28",{"name":5,"class":6},2]